利妥昔单抗、利那度胺、依鲁替尼联合化疗治疗ne患者疗效确切
合集下载
相关主题
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Adverse Events identified in >10% of patients
Presented By Jason Westin at 2019 ASCO Annual Meeting
Smart Start: <br />CNS Aspergillosis (n=1)
Presented By Jason Westin at 2019 ASCO Annual Meeting
Conclusions
Presented By Jason Westin at 2019 ASCO Annual Meeting
Conclusions
Presented By Jason Westin at 2019 ASCO Annual Meeting
Acknowledgements
Presented By Jason Westin at 2019 ASCO Annual Meeting
Rationale
Presented By Jason Westin at 2019 ASCO Annual Meeting
Synthetic Lethality of Lenalidomide and Ibrutinib
Presented By Jason Westin at 2019 ASCO Annual Meeting
Slide 11
Presented By Jason Westin at 2019 ASCO Annual Meeting
Disease burden change
Presented By Jason Westin at 2019 ASCO Annual Meeting
Smart Start: <br />PR after RLI 2 cycles (n = 29, 50%)<br />
Presented By Jason Westin at 2019 ASCO Annual Meeting
Survival
Presented By Jason Westin at 2019 ASCO Annual Meeting
Double Expressor
Presented By Jason Westin at 2019 ASCO Annual Meeting
Presented By Jason Westin at 2019 ASCO Annual Meeting
Background
Presented By Jason Westin at 2019 ASCO Annual Meeting
Previous DLBCL studiesຫໍສະໝຸດ Baidu
Presented By Jason Westin at 2019 ASCO Annual Meeting
Abstract 7508: <br />Smart Start: Final results of rituximab, lenalidomide, and ibrutinib lead in prior to combination with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma
Presented By Jason Westin at 2019 ASCO Annual Meeting
Smart Start: <br />RLI alone (n = 1)
Presented By Jason Westin at 2019 ASCO Annual Meeting
Smart Start: <br />PR after end of therapy (n = 2)
Study Design
Presented By Jason Westin at 2019 ASCO Annual Meeting
Results
Presented By Jason Westin at 2019 ASCO Annual Meeting
Therapy Received
Presented By Jason Westin at 2019 ASCO Annual Meeting